Chemotherapy and radiotherapy-induced nausea and vomiting are frequent, unpleasant side effects of cancer treatment.
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In childhood cancers, the optimal schedule of palonosetron has not been established yet. Kadota et al. 8 administered the drug at 3 or 10 mg/kg, and found these dosages equieffective and equitoxic. In a recent randomized trial, palonosetron was given at 0.25 mg per single dose and was found more effective than ondansetron. 9 No information is available for the population of children undergoing BMT.
We report herewith the results of a retrospective singleinstitution study whose aim was to evaluate the ability of palonosetron to prevent nausea and vomiting in children undergoing BMT. The study was approved by the institutional review board. Written informed consent was obtained from the patients' parents or legal guardians. The study was activated on 1 January 2007, and was closed to patient enrolment on 1 September 2009. In all, 43 children were registered for a total of 47 BMT procedures. Altogether, 29 patients were male and 14 were female. Median age at transplant was 10 years (range 1-18). Diagnoses included acute leukemias (n ¼ 22), lymphomas (n ¼ 3), solid tumors (n ¼ 13) and other hematological disorders (n ¼ 5) (see Table 1 ). In all, 4 of the 13 children with solid tumors received double transplants. A total of 26 BMTs were allogeneic and 21 were autologous. Patient characteristics are listed in Table 1 . The conditioning regimens varied depending on the underlying disease, type of transplant, and previous exposure to chemotherapeutic agents. Palonosetron was administered i.v. at the single 5 mg/kg dose, which was an intermediate one compared with previous authors'. 8 Symptom control along the length of conditioning regimen was defined (i) complete, when episodes of vomiting were 0-1 per day, and nausea was 10 (ii) partial, when vomiting episodes were 2-5 per day, but responded to dexamethasone, and (iii) poor, when vomiting episodes were 45 per day. Delayed vomiting that occurred after 410 days from starting the conditioning regimen was excluded from analysis, as it was considered possibly secondary to aplasia-related mucositis.
Nausea and vomiting were completely controlled by a single palonosetron dose for 32 of 47 transplants (68%), and partially controlled for additional 7 (15%), all responsive to dexamethasone. Finally, symptoms were poorly controlled for the last eight transplants (17%), but receded after a second drug dose given on day 5 of the conditioning regimen. Efficacy of palonosetron did not correlate with the underlying disease, nor with conditioning regimen (see Table 1 ). No adverse side effects attributable to the drug were reported.
Our data suggest that palonosetron is a valuable option for preventing chemotherapy and radiotherapy-induced nausea and vomiting in children undergoing BMT. Compared with other 5-HT3 RAs, palonosetron was more easily manageable and cost-effective, as efficacy was achieved with fewer administrations of the drug. In our study, by using 5 mg/kg single-dose schedule, only 17% of BMTs required a second drug dose, which was always effective and devoid of side effects. This is possibly the first report on testing palonosetron in children undergoing BMTs. Its efficacy, associated with the feasibility of administration and safety, suggest the possibility of its widespread use for preventing nausea and vomiting in children undergoing intensive conditioning regimens for BMT. Further studies on larger pediatric series are warranted.
